Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRISM: Jakafi and Zynyz in RCC and NSCLC
NCT07219576Phase 2Recruiting
- Sponsor
- University of California, San Diego
- Start
- Jan 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib in renal cell carcinoma (RCC), non-small cell lung carcinoma (NSCLC), sponsored by University of California, San Diego. Started Jan 2026; status: recruiting.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)non-small cell lung carcinoma (NSCLC)
Beyond the preview
Go deeper on NCT07219576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07219576.